Fritextsökning
Artiklar per år
Innehållstyper
-
Studie av fetmamedicin på paus
Ett läkemedel som Novo Nordisk tagit fram för behandling av diabetes typ II fungerar även som bantingsmedel. Det visar en fas II studie av preparatet. Men Novo Nordisk har lagt fortsatta studier på is.
-
Enklare RNA preparering med nytt system
NuGen lanserar Applause, ett nytt system för enklare förberedning av RNA.
-
Pengar och support på önskelistan
I senaste Scanbaltrapporten identifierar organisationen fem huvudområden för att förbättra förutsättningarna inom life scienceindustrin i länderna kringa Baltikum. -Självklart siktar vi högt, säger Scanbalts generaldirektör Peter Frank.
-
Sverige halkar efter med klinstudier
- För att klara konkurrensen måste vi få en mera forskningsinriktad sjukvård, kommenterar Olle Stendahl resultaten i Swedenbios årliga pipelinerapport.
-
Norge vill ha svensk kompetens
- Vi får tillgång till viktig norsk teknologi, säger Johan Schnürer. Som en del av det norska projektet Biomass to Biogas kommer norska forskare att samarbeta med Johan Schnürer och hans kollegor vid Sveriges lantbruksuniversitet, SLU.
-
Skräddarsydd jäst ger framtidens biobränsle
Ett nytt europeiskt samarbetsprojekt lett av finska VTT ska ta fram metoder för att tillverka biobränsle ur skogsavfall.
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
Äppelforskare får gastronomipris
2007 disputerade Åsa Jönsson vid SLU med en avhandling om ekologisk odling av äpplen, "Organic apple production in Sweden". Nu blir hennes avhandling prisbelönt.
-
Ingen USA-marknad för Vivostat
Vivostat har inte lyckats få in tillräcklig finansiering för att göra studier och få marknadsgodkännande i USA.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
BREAKING